(Q38061629)

PubMed publication ID

23172994

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23172994%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

review article

1 reference

title

LHRH Agonists for the Treatment of Prostate Cancer: 2012 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3503273&resulttype=core&format=json

8 May 2020

1 reference

Herbert Lepor

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3503273&resulttype=core&format=json

8 May 2020

Neal D Shore

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3503273&resulttype=core&format=json

8 May 2020

publication date

1 January 2012

1 reference

PubMed publication ID

23172994

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23172994%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3503273&resulttype=core&format=json

8 May 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3503273&resulttype=core&format=json

8 May 2020

issue

1-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3503273&resulttype=core&format=json

8 May 2020

page(s)

1-12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3503273&resulttype=core&format=json

8 May 2020

1 reference

12 December 2020

Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis

1 reference

12 December 2020

Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer

1 reference

12 December 2020

Insulin sensitivity during combined androgen blockade for prostate cancer

1 reference

12 December 2020

Follicle-stimulating hormone (FSH) escape during chronic gonadotropin-releasing hormone (GnRH) agonist and testosterone treatment

1 reference

12 December 2020

Progressive osteoporosis during androgen deprivation therapy for prostate cancer

1 reference

12 December 2020

Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

1 reference

12 December 2020

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies

1 reference

12 December 2020

Hormonal therapy in prostate cancer: historical approaches

1 reference

12 December 2020

Total testosterone, free-androgen index, calculated free testosterone, and free testosterone by analog RIA compared in hirsute women and in otherwise-normal women with altered binding of sex-hormone-binding globulin.

1 reference

12 December 2020

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology

1 reference

12 December 2020

Clinical practice. Osteoporosis in men.

1 reference

12 December 2020

Follicle-stimulating hormone promotes RANK expression on human monocytes

1 reference

12 December 2020

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)

1 reference

12 December 2020

Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature

1 reference

12 December 2020

Are gonadotrophins tumorigenic--a critical review of clinical and experimental data

1 reference

12 December 2020

Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making

1 reference

12 December 2020

The Effects of Orchidectomy, Estrogens, and Cyproterone Acetate on Plasma Testosterone, LH, and FSH Concentrations in Patients with Carcinoma of the Prostate

1 reference

12 December 2020

Mortality results from a randomized prostate-cancer screening trial

1 reference

12 December 2020

Ciba Corning ACS:180 testosterone assay evaluated.

1 reference

12 December 2020

Endocrine therapy for prostate cancer

1 reference

12 December 2020

Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994.

1 reference

12 December 2020

Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue

1 reference

12 December 2020

Purification of a human prostate specific antigen. 1979.

1 reference

12 December 2020

Effects of castration on androstenedione, testosterone and dihydrotestosterone plasma levels in adult male rats

1 reference

12 December 2020

Humoral mechanisms in prostate cancer: A role for FSH

1 reference

12 December 2020

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

1 reference

12 December 2020

Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer

1 reference

12 December 2020

The androgen axis in recurrent prostate cancer

1 reference

12 December 2020

Inhibition of testicular luteinizing hormone receptor level by treatment with a potent luteinizing hormone-releasing hormone agonist of human chorionic gonadotropin

1 reference

12 December 2020

Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer

1 reference

12 December 2020

Will GnRH antagonists improve prostate cancer treatment?

1 reference

12 December 2020

Randomized clinical trials of combined estrogen-androgen preparations: effects on sexual functioning

1 reference

12 December 2020

An update on androgen deprivation therapy for prostate cancer

1 reference

12 December 2020

Influence of publication of US and European prostate cancer screening trials on PSA testing practices.

1 reference

12 December 2020

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

1 reference

12 December 2020

Screening for prostatic carcinoma with prostate specific antigen

1 reference

12 December 2020

An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate

1 reference

12 December 2020

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

1 reference

12 December 2020

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

1 reference

12 December 2020

Hormone therapy in the management of prostate cancer: evidence-based approaches

1 reference

12 December 2020

Abiraterone and increased survival in metastatic prostate cancer

1 reference

12 December 2020

Skeletal fractures negatively correlate with overall survival in men with prostate cancer

1 reference

12 December 2020

Maximal androgen blockade for advanced prostate cancer

1 reference

12 December 2020

The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight

1 reference

12 December 2020

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

1 reference

12 December 2020

Gonadotropin-releasing hormone agonists in the treatment of prostate cancer

1 reference

12 December 2020

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916

1 reference

12 December 2020

Castration-resistant prostate cancer: many treatments, many options, many challenges ahead

1 reference

12 December 2020

Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

1 reference

12 December 2020

Hypothalamic follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-regulating hormone: structure, physiology, and clinical studies

1 reference

12 December 2020

Risk of fracture after androgen deprivation for prostate cancer

1 reference

12 December 2020

Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?

1 reference

12 December 2020

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up

1 reference

12 December 2020

Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR)

1 reference

12 December 2020

Impact of androgen deprivation therapy on cardiovascular disease and diabetes.

1 reference

12 December 2020

Metabolic complications of androgen deprivation therapy for prostate cancer

1 reference

12 December 2020

Changes in body composition during androgen deprivation therapy for prostate cancer

1 reference

12 December 2020

Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.

1 reference

12 December 2020

Screening and prostate-cancer mortality in a randomized European study

1 reference

12 December 2020

Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force

1 reference

12 December 2020

Intermittent androgen deprivation therapy: redefining the standard of care?

1 reference

12 December 2020

Is disease flare a problem?

1 reference

12 December 2020

Randomized clinical trial of a family intervention for prostate cancer patients and their spouses

1 reference

12 December 2020

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

1 reference

12 December 2020

Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.

1 reference

12 December 2020

Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer

1 reference

12 December 2020

Prostate cancer incidence and mortality rates and trends in the United States and Canada

1 reference

12 December 2020

Radical prostatectomy versus watchful waiting in early prostate cancer

1 reference

12 December 2020

Expression of follicle-stimulating hormone receptor in tumor blood vessels

1 reference

12 December 2020

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3503273&resulttype=core&format=json

8 May 2020

PubMed publication ID

23172994

1 reference